Migraine is a type of neurological disorder which causes headache characterized by vomiting, extreme sensitivity to light, sound, and nausea. The types of migraine are without aura and with aura by the mean of common migraines as well as classical migraines. Usually, Women are more susceptible to suffer severe migraine than men. It is necessary to get a treatment for migraine by taking proper diagnosis and preventive medicines to avoid migraine attack. In terms of treating migraine, market players are investing constantly in research and development to get desired drugs and cure for the disease, further enhancing the global portfolio. With the continuous efforts and high R&D expenses, key players have got numerous successful drugs such as naproxen, sumatriptan, ibuprofen, zolmitriptan, and aspirin to treat or lower the ache or cure the migraine attack.
Increasing occurrences of migraine attack is anticipated to bolster growth for migraine drugs market.
Migraine is most common between the ages of 25 and 55 and this ailment is tending to run in family by mean that, approximately 90% cases of migraine cases do have family history for the disease. According to the Migraine Research Foundation, Migraine is the third most widespread neurological disease, affecting 39 million children, women, and men in the U.S. and 1 billion globally. Thus, growing number of people having migraine and high probabilities of occurrence of this illness along with its hereditary phenomena is anticipated to boost the global migraine drugs market in the forecast period. In addition, improved awareness for the migraine drugs and treatments, coupled with technological advancement for the manufacturing of anti-migraine drugs are other factors anticipated to propel the market growth.
However, concerns about reliability of pain killers and easy obtainability of the generic drugs in pharmacy stores are the factors restricting the growth of the migraine drugs market.
The global migraine drugs market is segmented on the basis of drug type, route of administration, distribution channel, and geography.
On the basis of Migraine drug type, the market is segmented into:
On the basis of route of administration, the Migraine Drugs market is segmented into:
On the basis of distribution channel, the Migraine Drugs market is segmented into:
Geographically, the global Migraine Drugs market is segmented into North America, Europe, Asia pacific, Latin America, and Middle East and Africa.
North America region observed to dominate the market due to rising incidences of migraine attacks and the high demand for drugs.
On the basis of geography, North America region is estimated to dominate the global migraine market. The high market growth in this region is attributed to factors such as increased healthcare expenditure and convenience of getting specialty migraine drugs. In addition, rising incidence of migraine attacks in U.S. and Canada is anticipated to boost the market growth in this region. According to Migraine Research Foundation, approximately 1 in 4 U.S. families includes a person with migraine disease. Moreover, at every 10 seconds, a person in the U.S. has to visit the emergency room complaining of head ache, and around 1.2 million hospital visits are due to acute migraine attacks. Thus, high incidence rate and growing demand for the drugs to treat or cure the migraine is further anticipated to bolster the market growth in North America.
However, Asia Pacific is anticipated to make significant growth during the forecast period. Rising population suffering from migraine and constant demand for migraine drugs is expected to drive the significant growth in this region.